Effects of Tacrolimus on Proteinuria in Chinese and Indian Patients with Idiopathic Membranous Nephropathy: the Results of Machine Learning Study

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Apr 20

PMID 38642210

Authors

Min Rui

Lei Jiang

Jia-Jun Pan

Xue-Ting Huang

Jia-Fang Cui

Shi-Jia Zhang

Su-Mei He

Huan-Huan Han

Xiao Chen

Dong-Dong Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: The present study aims to explore the effects of tacrolimus on proteinuria in patients with idiopathic membranous nephropathy (IMN) and recommend an appropriate dosage schedule via machine learning method.

Methods: The E model was constructed to analyze the effects of tacrolimus on proteinuria in patients with IMN. Data were mined from published literature and machine learning was built up with E model, among which the efficacy indicator was proteinuria change rates from baseline. 463 IMN patients were included for modeling, and tacrolimus therapeutic window concentrations were 4-10 ng/ml.

Results: In machine learning model, the E from tacrolimus effecting proteinuria in IMN patients was -72.7%, the ET was 0.43 months, and the time to achieving 25% E, 50% E, 75% E, and 80% (plateau) E of tacrolimus on proteinuria in patients with IMN were 0.15, 0.43, 1.29, and 1.72 months, respectively.

Conclusion: For achieving better therapeutic effects from tacrolimus on proteinuria in patients with IMN, tacrolimus concentration range need to be maintained at 4-10 ng/ml for at least 1.72 months.

References

Beck Jr L, Salant D . Membranous nephropathy: from models to man. J Clin Invest. 2014; 124(6):2307-14. PMC: 4089468. DOI: 10.1172/JCI72270. View

Huang H, Liang Z, Zheng X, Qing Q, Du X, Tang Z . Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials. Ren Fail. 2021; 43(1):840-850. PMC: 8158268. DOI: 10.1080/0886022X.2021.1914655. View

Zhang X, Cui Z, Zhang M, Wang J, Zhang Y, Qu Z . Clinical implications of pathological features of primary membranous nephropathy. BMC Nephrol. 2018; 19(1):215. PMC: 6114049. DOI: 10.1186/s12882-018-1011-5. View

Hladunewich M, Troyanov S, Calafati J, Cattran D . The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009; 4(9):1417-22. PMC: 2736692. DOI: 10.2215/CJN.01330209. View

Glassock R . Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003; 23(4):324-32. DOI: 10.1016/s0270-9295(03)00049-4. View

Schieppati A, Mosconi L, Perna A, MECCA G, Bertani T, Garattini S . Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993; 329(2):85-9. DOI: 10.1056/NEJM199307083290203. View

Wasserstein A . Membranous glomerulonephritis. J Am Soc Nephrol. 1997; 8(4):664-74. DOI: 10.1681/ASN.V84664. View

van den Brand J, van Dijk P, Hofstra J, Wetzels J . Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014; 9(6):1066-73. PMC: 4046727. DOI: 10.2215/CJN.08880813. View

Jardine A . Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int. 2005; 18(4):379-84. DOI: 10.1111/j.1432-2277.2005.00080.x. View

10.

Caro J, Gutierrez-Solis E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C . Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 2014; 30(3):467-74. DOI: 10.1093/ndt/gfu306. View

11.

Li Z, Hu M, Zhang C, Wang Y . Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015; 35(5):623-628. DOI: 10.1007/s11596-015-1480-8. View

12.

Zhang X, Ji C, Yuan J, Wang L, Zhang J, Fang W . Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study. Kaohsiung J Med Sci. 2019; 35(10):633-639. DOI: 10.1002/kjm2.12098. View

13.

Di J, Qian Q, Yang M, Jiang Y, Zhou H, Li M . Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy. Exp Ther Med. 2018; 16(2):979-984. PMC: 6090310. DOI: 10.3892/etm.2018.6211. View

14.

Shang S, Cai G, Duan S, Li P, Li Q, Chen X . Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy. BMC Nephrol. 2018; 19(1):182. PMC: 6052665. DOI: 10.1186/s12882-018-0967-5. View

15.

Liang Q, Li H, Xie X, Qu F, Li X, Chen J . The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017; 39(1):512-518. PMC: 6014322. DOI: 10.1080/0886022X.2017.1325371. View

16.

Cui W, Lu X, Min X, Liu M, Guan S, Wang Y . Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Braz J Med Biol Res. 2017; 50(4):e5976. PMC: 5423753. DOI: 10.1590/1414-431X20175976. View

17.

Liu S, Li X, Li H, Liang Q, Chen J, Chen J . Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. BMC Nephrol. 2015; 16:200. PMC: 4669631. DOI: 10.1186/s12882-015-0199-x. View

18.

Ramachandran R, Hn H, Kumar V, Nada R, Yadav A, Goyal A . Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton). 2015; 21(2):139-46. DOI: 10.1111/nep.12569. View

19.

Yuan H, Liu N, Sun G, Jia Y, Luo P, Miao L . Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology. 2013; 91(5-6):259-66. DOI: 10.1159/000348570. View

20.

Chen M, Li H, Li X, Lu F, Ni Z, Xu F . Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3):233-8. DOI: 10.1097/MAJ.0b013e3181ca3a7d. View